Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Date first appeared online 23/03/2017
DOI 10.1016/S2213-8587(17)30085-2
Authors Bain S.
Journal Name The Lancet Diabetes and Endocrinology
Volume 5

Documents